May 16, 2018 / 5:05 AM / 6 months ago

BRIEF-Regeneron says Phase 3 Trial Of Dupixent Met Primary Endpoints

May 16 (Reuters) - Regeneron Pharmaceuticals Inc:

* POSITIVE PHASE 3 TRIAL OF DUPIXENT® (DUPILUMAB) IN ADOLESCENTS WITH INADEQUATELY CONTROLLED MODERATE-TO-SEVERE ATOPIC DERMATITIS

* U.S. REGULATORY SUBMISSION FOR PATIENTS AGES 12-17 PLANNED FOR Q3 2018

* CO, SANOFI SAID PIVOTAL PHASE 3 TRIAL EVALUATING DUPIXENT MET PRIMARY AND KEY SECONDARY ENDPOINTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below